- Loss of Smell More Common in COVID-19 Than Thought
- Psoriasis Meds Don’t Raise Risk of Severe COVID-19: Study
- Diet Drinks Don’t Do Your Heart Any Favors
- Lockdowns Can Widen Kids’ Waistlines – Here’s How to Curb That
- Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectivenes
- Health Highlights: Oct. 27, 2020
- Kidney Trouble Greatly Raises Odds for Fatal COVID-19
- MRIs Might Be Safe for Patients With Implanted Heart Devices
- More Evidence Masks Slow COVID’s Spread
- Dangerous COVID-19 Syndrome First Seen in Kids Also Strikes Adults
TachoSil Sealant Patch Approved for Cardiovascular Surgery
MONDAY, April 5The TachoSil sealant patch has been approved by the U.S. Food and Drug Administration to prevent bleeding from small blood vessels in certain cardiovascular surgery cases, the agency said Monday.
The product is comprised of a collagen sponge, produced from horse tendons, that is coated with two proteins, fibrinogen and thrombin. The proteins trigger a series of chemical reactions that produce fibrin, a stringy protein that fosters production of a blood clot.
The biodegradable patch is designed to break down inside the body within six months. Plasma used in the product’s manufacture is screened for blood-borne diseases, the FDA said, and the collagen taken from horse tendons is filtered from impurities, including viruses that affect horses.
In clinical testing involving 119 people, 74.6 percent of patch users stopped bleeding within three minutes, compared with 33.3 percent among those who didn’t get the patch. Possible side effects include allergic reactions, the FDA said.
The product is manufactured by Nycomed Austria.
More information
The FDA has more about this approval.
Source: HealthDay
